{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"SI-053"},{"type":"Synonym","name":"Temodex"},{"type":"CodeName","name":"SI053"},{"type":"CodeName","name":"SI 053"},{"type":"Synonym","name":"temozolomide formulation SI-053"},{"type":"Synonym","name":"TMZ formulation SI-053"},{"type":"Synonym","name":"temozolomide-based SI-053"}],"definition":{"html":"A powder for gel formulation containing the cytotoxic alkylating agent temozolomide (TMZ), an imidazotetrazine derivative of the alkylating agent dacarbazine, immobilized on the polymeric carrier dextran phosphate, with potential antineoplastic activity. The TMZ formulation SI-053 forms a viscous gel upon reconstitution in water. Upon local intraoperative administration of the gel into the cavity that is formed after resection of the brain tumor, SI-053 allows for local and prolonged action of TMZ. TMZ is converted at physiologic pH to the short-lived active compound 5-(3-methyl-(triazen-1-yl)-imidazole)-4-carboxamide (monomethyltriazenoimidazole carboxamide; MTIC). The cytotoxicity of MTIC is due to methylation of DNA, particularly at the O6 and N7 positions of guanine residues, resulting in cell cycle arrest, inhibition of DNA replication and the induction of apoptosis. The local administration of TMZ allows for the local destruction of the remaining tumor cells immediately after the removal of the tumor and may prevent the recurrence of tumor growth while having no severe systemic toxicity.","text":"A powder for gel formulation containing the cytotoxic alkylating agent temozolomide (TMZ), an imidazotetrazine derivative of the alkylating agent dacarbazine, immobilized on the polymeric carrier dextran phosphate, with potential antineoplastic activity. The TMZ formulation SI-053 forms a viscous gel upon reconstitution in water. Upon local intraoperative administration of the gel into the cavity that is formed after resection of the brain tumor, SI-053 allows for local and prolonged action of TMZ. TMZ is converted at physiologic pH to the short-lived active compound 5-(3-methyl-(triazen-1-yl)-imidazole)-4-carboxamide (monomethyltriazenoimidazole carboxamide; MTIC). The cytotoxicity of MTIC is due to methylation of DNA, particularly at the O6 and N7 positions of guanine residues, resulting in cell cycle arrest, inhibition of DNA replication and the induction of apoptosis. The local administration of TMZ allows for the local destruction of the remaining tumor cells immediately after the removal of the tumor and may prevent the recurrence of tumor growth while having no severe systemic toxicity."},"drugInfoSummaryLink":null,"nciConceptId":"C181749","nciConceptName":"Locally-acting Temozolomide Formulation SI-053","termId":805853,"name":"locally-acting temozolomide formulation SI-053","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"locally-acting-temozolomide-formulation-si-053"},{"aliases":[{"type":"CodeName","name":"SCH 52365"},{"type":"Abbreviation","name":"TMZ"},{"type":"ForeignBrandName","name":"Temodal"},{"type":"ForeignBrandName","name":"Temomedac"},{"type":"USBrandName","name":"Temodar"},{"type":"ChemicalStructureName","name":"3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide"},{"type":"ChemicalStructureName","name":"8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one"},{"type":"CodeName","name":"CCRG-81045"},{"type":"CodeName","name":"M & B 39831"},{"type":"LexicalVariant","name":"M and B 39831"},{"type":"ObsoleteName","name":"Methazolastone"},{"type":"CodeName","name":"RP-46161"},{"type":"ChemicalStructureName","name":"imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-"},{"type":"ForeignBrandName","name":"Gliotem"},{"type":"ForeignBrandName","name":"Temizole"},{"type":"CASRegistryName","name":"85622-93-1"},{"type":"ForeignBrandName","name":"Temcad"}],"definition":{"html":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system.","text":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/temozolomide","text":"Temozolomide"},"nciConceptId":"C1244","nciConceptName":"Temozolomide","termId":41671,"name":"temozolomide","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"temozolomide"}],"links":null}